Sen-Jam Pharmaceutical, a developer of precision remedies to address chronic inflammation and metabolic disorders, announced on Tuesday that it has received ethics approval for a clinical trial of its flagship asset, SJP-001, in Australia.

The trial is intended to assess the the efficacy and safety of SJP-001, an over-the-counter therapeutic targeting metabolic health and relief from overindulgence in food and drink, including its effects on inflammatory pathways.

This milestone paves the way for the product to advance through clinical evaluation, with the trial carried out by Nucleus Network, an Australian early-phase clinical research organisation, and supported by contract research organisation Novotech.

The SJP-001 clinical trial is designed to assess the product's ability to modulate inflammation and improve metabolic outcomes, providing relief from the after effects of dietary overindulgence while supporting long-term metabolic health.